Mary‐Kate Malecek
A5069849982- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Sarcoma Diagnosis and Treatment
- Moyamoya disease diagnosis and treatment
- Cancer-related Molecular Pathways
- Glioma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Lipoproteins and Cardiovascular Health
- Metabolism, Diabetes, and Cancer
- Melanoma and MAPK Pathways
- Radiomics and Machine Learning in Medical Imaging
- PI3K/AKT/mTOR signaling in cancer
- T-cell and Retrovirus Studies
- Cutaneous Melanoma Detection and Management
- Esophageal Cancer Research and Treatment
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Cells and Metastasis
- Multiple Myeloma Research and Treatments
- Cutaneous lymphoproliferative disorders research
- Cancer Treatment and Pharmacology
Washington University in St. Louis
2018-2023
Northwestern University
2015-2017
There is a paucity of large-scale data delineating outcomes and prognostication older patients with primary central nervous system lymphoma (PCNSL). We retrospectively analyzed 539 newly-diagnosed PCNSL ages ≥60 years across 20 U.S. academic centers. The median age was 70 (range 60-88); at least one geriatric syndrome present in 46%; the Cumulative Index Ratings Scale-Geriatrics (CIRS-G) score 6 (range, 0-27); 36% had impairment activities daily living (ADL). most common induction regimens...
Although an expanding array of effective treatments has resulted in recent improvement survival patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification prognostic factors remains a priority. We assessed the impact time to progression disease (POD) after first-line therapy among 455 relapsed MCL. Patients were categorized by duration first remission as PRF/POD6, defined progressive during induction or POD within 6 months diagnosis (n = 65; 14%); POD6-24,...
Abstract Clinical outcomes and predictors of survival in patients with newly diagnosed mantle cell lymphoma (MCL) treated the rituximab era (2000–2015) at 12 US academic centers were assessed to identify determinants across age groups. Objectives characterize compare practice patterns, prognostic factors for younger (age < 65) older ≥ 65 years). Among 1162 included, 697 465 older. In patients, 2‐year progression free (PFS) overall (OS) rates 79% 92% respectively; blastoid histology, ECOG...
We performed a multicenter retrospective analysis across 10 US academic medical centers to evaluate treatment patterns and outcomes in patients age ≥60 years with classic Hodgkin lymphoma (cHL) from 2010-2018. Among 244 eligible patients, median was 68, 63% had advanced stage (III/IV), 96% Eastern Cooperative Oncology Group performance status (PS) 0-2, 12% documented loss of ≥1 activity daily living (ADL). Medical comorbidities were assessed by the Cumulative Illness Rating Scale-Geriatric...
The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. Among 309 CNSL patients aged ≥60, 11.7% had EBV + tumors which 72.2% were solid organ transplant (SOT)-related post-transplant lymphoproliferative disorders (PTLD). Younger age, SOT or autoimmune disease, immunosuppressive treatment correlated highly EBV-positivity. absent...
The prognostic relevance of diagnosis to treatment interval (DTI) in patients with newly diagnosed mantle cell lymphoma (MCL) is unknown. Hence, we sought evaluate the impact DTI on outcomes MCL using 3 large datasets (1) University Iowa/Mayo Clinic Specialized Program Research Excellence Molecular Epidemiology Resource, (2) enrolled ALL Age Asthma Cohort/CALGB 50403, and (3) a multisitecohort MCL. Patients were priori divided into 2 groups, 0 14 days (short DTI) 15 60 (long DTI). whom...
Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) is a rare but serious complication that carries poor prognosis. The use of infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) for frontline treatment diffuse large B cell (DLBCL) increasing, though little known about incidence risk factors CNS with this regimen PATIENTS AND METHODS: We completed chart review patients NHL who received EPOCH-R as front line therapy. Data...
Introduction: Bendamustine + rituximab (BR) is frequently utilized as initial treatment for patients (pts) with mantle cell lymphoma (MCL). Following induction BR, the role of maintenance (MR) controversial and practice patterns vary. MR improves overall survival (OS) in younger pts following autologous stem transplantation (ASCT) older R-CHOP. However, a preliminary analysis randomized phase 3 MAINTAIN study revealed neither progression-free (PFS) nor OS benefit versus observation MCL...
While most patients with mantle cell lymphoma (MCL) receive therapy shortly after diagnosis, a subset of indolent-behaving disease can safely defer treatment. In this subgroup, we evaluated the importance treatment intensity in MCL who initial therapy.Out 1134 from 12 academic centers, analyzed 219 initiated at least 90 days diagnosis. Patients received induction high-dose cytarabine and/or autologous stem transplantation (ASCT) first remission were considered to have intensive (n = 88)...